A Disease That Demands a Cure, Not Better Management
Type 1 diabetes (T1D) is one of the cruelest autoimmune diseases. The body's own immune system -- specifically autoreactive T cells -- systematically destroys the insulin-producing beta cells in the pancreatic islets of Langerhans. Once enough beta cells are gone, the body can no longer regulate blood glucose. Without exogenous insulin, death follows within weeks. With it, patients face a lifetime of relentless management: multiple daily injections or insulin pump therapy, continuous glucose monitoring, carbohydrate counting, and the constant threat of hypoglycemic episodes and long-term complications including cardiovascular disease, kidney failure, nerve damage, and blindness.
Approximately 8.7 million people worldwide live with Type 1 diabetes, according to estimates published in The Lancet Diabetes & Endocrinology in 2022 (Lancet, 2022). Unlike Type 2 diabetes, which is driven by insulin resistance and is often associated with lifestyle factors, T1D is an autoimmune condition that typically presents in childhood or adolescence. It is not preventable with current knowledge, and it is not curable with current treatments.
Every existing therapy for T1D -- insulin injections, insulin pumps, continuous glucose monitors (CGMs), hybrid closed-loop systems -- manages the downstream consequence of beta cell destruction. None of them address the root cause. None of them replace what was lost.
That is what makes gene editing's approach to T1D so fundamentally different. Instead of managing the absence of beta cells, researchers are now using CRISPR to create new ones -- derived from stem cells, engineered for immune evasion, and designed to restore the body's own insulin production. If it works, it would represent the first true functional cure for Type 1 diabetes.
A mouse pancreatic islet of Langerhans with insulin-producing beta cells (green) and glucagon-producing alpha cells (red). Image: Wikimedia Commons, CC BY-SA 3.0.
The Biology of the Problem: Why T1D Is So Hard to Cure
To understand why gene editing represents such a significant advance, it is necessary to understand the specific biological challenges that T1D presents to any curative approach.
The Autoimmune Attack
T1D is driven by a breakdown in immune self-tolerance. In healthy individuals, the immune system learns during development to distinguish self-tissues from foreign invaders. In T1D, this process fails for pancreatic beta cells. Autoreactive CD4+ and CD8+ T cells infiltrate the pancreatic islets and selectively destroy cells expressing insulin and related beta cell antigens. This process, called insulitis, is progressive and often begins years before clinical symptoms appear.
The autoimmune nature of the disease creates a fundamental problem for any cell replacement strategy: if you transplant new beta cells into a patient with T1D, the same immune attack that destroyed the original beta cells will destroy the replacements. This is true even if the replacement cells are the patient's own stem-cell-derived beta cells -- the autoimmune memory persists.
The Alloimmune Barrier
Even if the autoimmune attack could be controlled, there is a second immunological barrier. Unless replacement beta cells are derived from the patient's own tissue (autologous), they will express foreign HLA molecules on their surface. The recipient's immune system will recognize these as non-self and mount a classic transplant rejection response. This is the same alloimmune rejection that limits organ transplantation and requires lifelong immunosuppression.
The Vascularization Problem
Beta cells in the native pancreas are among the most highly vascularized cells in the body. Each islet is penetrated by a dense capillary network that delivers oxygen and nutrients and allows beta cells to sense blood glucose levels in real time. When beta cells are transplanted -- whether from cadaveric donors or derived from stem cells -- they must rapidly establish a new blood supply at the graft site. Until they do, many cells die from hypoxia. Inadequate vascularization is one of the primary reasons that islet transplantation outcomes have historically been inconsistent.
The Glucose-Sensing Challenge
A functioning beta cell does not simply produce insulin. It acts as a sophisticated glucose sensor, releasing precisely calibrated amounts of insulin in response to fluctuations in blood glucose -- more after a meal, less during fasting, with rapid adjustments in both directions. Any cell replacement therapy must produce cells that replicate this dynamic, glucose-responsive insulin secretion. Static insulin production -- cells that simply leak insulin at a constant rate -- would be insufficient and potentially dangerous.
As Dr. Douglas Melton, a pioneering stem cell researcher at Harvard University whose work has been foundational to the field, has stated: "The challenge is not just making cells that produce insulin. The challenge is making cells that produce the right amount of insulin at the right time" (Harvard Stem Cell Institute).
The Current Standard of Care: Better Management, Not a Cure
Before examining how gene editing aims to transform T1D treatment, it is important to acknowledge how far management technology has come -- and where its limits remain.
Modern T1D management revolves around three technologies: insulin delivery (injections or pumps), glucose monitoring (finger-stick meters or CGMs), and increasingly, hybrid closed-loop systems that partially automate insulin dosing based on CGM data.
Continuous glucose monitors like those made by Dexcom and Abbott have been transformative. They provide real-time glucose readings every five minutes, alerting patients to dangerous highs and lows. When paired with insulin pumps in hybrid closed-loop configurations -- sometimes called "artificial pancreas" systems -- they can maintain glucose levels within target range for a higher percentage of the day than manual management allows.
But even the best closed-loop systems have significant limitations. They cannot fully replicate the speed and precision of native beta cell insulin secretion. They require ongoing device management, sensor changes, infusion site rotations, and troubleshooting. They are expensive, and access remains uneven globally. Most importantly, they are still managing a chronic condition, not curing it. Patients remain dependent on external devices and synthetic insulin for every day of their lives.
"We have gotten remarkably good at keeping people alive with Type 1 diabetes," noted Dr. Camillo Ricordi, director of the Diabetes Research Institute at the University of Miami. "But surviving is not the same as being cured. These patients deserve better" (Diabetes Research Institute).
Islet Transplantation: The Proof of Concept That Hit a Wall
The idea that transplanting insulin-producing cells could cure T1D is not new. Cadaveric islet transplantation has been performed for over two decades, with the landmark Edmonton Protocol, published in 2000 by Dr. James Shapiro and colleagues at the University of Alberta, demonstrating that transplanted islets from deceased donors could achieve insulin independence in patients with severe T1D (Shapiro et al., NEJM, 2000).
The Edmonton Protocol was a proof of concept that cell replacement could work. But it also revealed the limits of the approach. Multiple donor pancreases were required for each recipient because so many islets were lost during isolation and transplantation. Only a small fraction of patients maintained insulin independence beyond five years. And lifelong immunosuppression was required to prevent rejection -- immunosuppression that carried its own risks of infection, malignancy, and organ toxicity.
These limitations -- donor scarcity, cell loss, and the immunosuppression burden -- are precisely the challenges that gene editing and stem cell technology now aim to overcome.
Stem Cell-Derived Beta Cells: The Renewable Source
The first critical breakthrough was learning to make beta cells from stem cells. If you can derive unlimited quantities of functional, glucose-responsive beta cells from human pluripotent stem cells -- either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) -- you eliminate the donor scarcity problem entirely.
Directed differentiation of iPSCs into insulin-producing beta cells involves a multi-step process mimicking pancreatic development. Image: Wikimedia Commons, CC BY-SA 4.0.
Douglas Melton's laboratory at Harvard spent over 15 years developing protocols to differentiate human pluripotent stem cells into functional beta cells through a series of carefully orchestrated steps that recapitulate pancreatic development. The process guides stem cells through definitive endoderm, posterior foregut, pancreatic progenitor, endocrine progenitor, and finally mature beta cell stages using specific combinations of growth factors, small molecules, and culture conditions at each step.
In 2014, Melton and colleagues published a landmark paper in Cell describing the generation of stem cell-derived beta cells (SC-beta cells) that were functionally mature -- they expressed insulin, responded to glucose stimulation in a dose-dependent manner, and, when transplanted into diabetic mice, restored glycemic control within weeks (Pagliuca et al., Cell, 2014).
This was a pivotal moment. It established that the manufacturing problem was solvable. But the immunology problem remained. These SC-beta cells still expressed surface antigens that would trigger both autoimmune recurrence and alloimmune rejection. Transplanting them without immunosuppression would be futile.
CRISPR Therapeutics and the CTX211 Program
This is where CRISPR enters the story -- and where the field makes its most ambitious leap.
CRISPR Therapeutics, the company co-founded by Nobel laureate Emmanuelle Charpentier and best known for Casgevy (the first FDA-approved CRISPR therapy, for sickle cell disease), has developed a program called CTX211 that combines stem cell-derived beta cell manufacturing with CRISPR-mediated immune evasion engineering. The program, conducted in collaboration with ViaCyte (which was acquired by Vertex Pharmaceuticals in 2022), represents one of the most sophisticated applications of gene editing in regenerative medicine.
How CTX211 Works
The CTX211 approach begins with human induced pluripotent stem cells (iPSCs) -- adult cells that have been reprogrammed back to a pluripotent state, giving them the capacity to differentiate into virtually any cell type. These iPSCs are then edited using CRISPR-Cas9 to introduce a specific set of genetic modifications designed to make the resulting cells invisible to the immune system:
HLA class I knockout (B2M disruption): The beta-2-microglobulin (B2M) gene is disrupted, which prevents the assembly and surface expression of all HLA class I molecules. This makes the cells invisible to CD8+ cytotoxic T cells, which require HLA class I to recognize and kill target cells. This single edit addresses a major component of both alloimmune rejection and autoimmune recurrence.
HLA class II prevention (CIITA disruption): The class II major histocompatibility complex transactivator (CIITA) gene is disrupted, preventing expression of HLA class II molecules. This blocks recognition by CD4+ helper T cells, removing another arm of the adaptive immune response.
NK cell evasion (CD47 overexpression or HLA-E insertion): Knocking out HLA class I creates a new problem -- cells lacking HLA class I become targets for natural killer (NK) cells, which are programmed to destroy cells that fail to display these molecules (the "missing self" hypothesis). To counter this, CTX211 cells are engineered to overexpress immunomodulatory molecules such as CD47 (a "don't eat me" signal) or to express HLA-E, a non-classical MHC molecule that inhibits NK cell activation without triggering T cell recognition.
After these edits are made at the iPSC stage, the edited cells are differentiated into mature, glucose-responsive beta cells using directed differentiation protocols. The result is a population of insulin-producing cells that are functionally equivalent to native beta cells but are engineered to evade the immune system -- what researchers call "universal donor" or "hypoimmunogenic" cells.
"What we are doing is creating an immune-privileged cell that can go into any patient without the need for immunosuppression," explained Dr. Pankaj Bhatt, then chief scientific officer at CRISPR Therapeutics. "That is the holy grail of cell therapy -- not just for diabetes, but for any condition where you need to replace lost or damaged cells" (CRISPR Therapeutics Pipeline).
The CRISPR-Cas9 system uses a guide RNA to direct the Cas9 nuclease to specific DNA sequences for precise genetic editing. Image: Wikimedia Commons, CC BY-SA 4.0.
Vertex Pharmaceuticals: VX-880, VX-264, and the Race to Clinical Proof
While CRISPR Therapeutics approaches T1D through iPSC-derived, gene-edited cells, Vertex Pharmaceuticals has pursued a parallel path that has generated some of the most compelling clinical data in the field.
VX-880: First-in-Human Proof That Stem Cell-Derived Beta Cells Work
VX-880 consists of stem cell-derived, fully differentiated pancreatic islet cells infused directly into the hepatic portal vein -- the same route used in the Edmonton Protocol for cadaveric islet transplantation. Unlike the CRISPR Therapeutics approach, VX-880 does not incorporate gene editing for immune evasion. Patients receive conventional immunosuppression to prevent rejection.
Despite this limitation, VX-880 has produced remarkable results. In clinical trials, patients with T1D who had no residual insulin production achieved measurable and clinically significant restoration of insulin secretion, as demonstrated by increased C-peptide levels (a biomarker for endogenous insulin production). Some patients achieved insulin independence -- they stopped needing exogenous insulin entirely -- for the first time in years or decades (Vertex Pharmaceuticals Press Release, 2023).
These results are historically significant. They represent the first demonstration that stem cell-derived beta cells, manufactured at scale, can restore meaningful insulin production in humans. The results validated the entire scientific premise -- that you can take a stem cell, turn it into a beta cell in a laboratory, put it into a person, and have it function as a glucose-responsive insulin factory.
"The VX-880 data are a watershed moment for the field," stated Dr. Manasi Sinha Jaiman, an endocrinologist specializing in T1D. "For the first time, we have clinical evidence that manufactured beta cells can do the job of native beta cells in human patients. The question is no longer whether this can work -- it is how to make it work without lifelong immunosuppression."
VX-264: The Encapsulation Approach
Recognizing that immunosuppression is the primary barrier to broad adoption, Vertex developed VX-264, which uses the same stem cell-derived islet cells as VX-880 but delivers them in an implantable encapsulation device rather than as a direct infusion.
The encapsulation device is designed with a semipermeable membrane that allows small molecules -- glucose, insulin, oxygen, nutrients -- to pass through while blocking immune cells and antibodies. In principle, this physical barrier eliminates the need for immunosuppression by preventing the immune system from ever contacting the transplanted cells.
Encapsulation is an elegant concept, but its execution has proven enormously challenging. Early clinical data from VX-264 have been mixed, with patients showing lower levels of insulin secretion compared to VX-880. The likely culprit is the fundamental tension at the heart of encapsulation: the membrane must be porous enough to allow rapid glucose sensing and insulin release but impermeable enough to exclude immune cells. And the encapsulated cells must survive with limited direct vascularization, relying on diffusion for oxygen delivery -- a constraint that limits the number of viable cells within each device.
The encapsulation approach remains an active area of research, but the field has increasingly focused on the gene-editing approach to immune evasion as the more promising long-term solution.
Sernova and Other Approaches: Expanding the Field
The T1D cell therapy landscape extends beyond CRISPR Therapeutics and Vertex. Several other companies and academic groups are pursuing distinct strategies.
Sernova Corp has developed the Cell Pouch System, an implantable, pre-vascularized device that creates a subcutaneous environment for islet cell engraftment. The approach addresses the vascularization problem by implanting the empty device first, allowing the body to grow blood vessels into and around it over several weeks, and then injecting islet cells into the vascularized pouch. Early clinical data have shown detectable C-peptide production and reduced insulin requirements in some patients (Sernova Corp).
Sigilon Therapeutics (now part of Eli Lilly) developed engineered cell therapies enclosed in immunoprotective capsules using modified alginate hydrogels designed to resist fibrotic overgrowth -- a common failure mode for encapsulation devices.
Academic groups at institutions including the Massachusetts Institute of Technology, the University of British Columbia, and the Joslin Diabetes Center continue to push the boundaries of both cell engineering and immunoprotection strategies.
The Gene Editing Advantage: Creating Universal Donor Islet Cells
The concept of "universal donor" cells -- cells that can be transplanted into any recipient without immunosuppression -- is not unique to diabetes. It is being pursued across regenerative medicine, from cardiac repair to neurological diseases. But T1D is arguably the indication where the concept is most advanced and most consequential.
The gene-editing strategy for creating universal donor islet cells involves a combination of gene knockouts and gene insertions:
| Edit | Target Gene | Purpose |
|---|---|---|
| Knockout | B2M | Eliminates HLA class I surface expression, preventing CD8+ T cell recognition |
| Knockout | CIITA | Prevents HLA class II expression, blocking CD4+ T cell activation |
| Knock-in | CD47 | Overexpresses "don't eat me" signal, inhibiting macrophage phagocytosis |
| Knock-in | HLA-E | Expresses NK cell inhibitory ligand, preventing "missing self" killing |
| Knock-in | PD-L1 | Expresses immune checkpoint ligand, inducing T cell exhaustion at the graft site |
This multi-edit strategy is designed to defeat every arm of the immune response simultaneously: adaptive immunity (T cells), innate immunity (NK cells and macrophages), and autoimmune memory. If successful, it would eliminate the need for immunosuppression entirely -- transforming cell replacement therapy from a procedure that trades one form of lifelong medical dependency (insulin) for another (immunosuppressants) into a genuine, standalone cure.
Clinical Trial Landscape and Regulatory Status
As of late 2025, the clinical trial landscape for gene-edited and stem cell-derived beta cell therapies includes several active programs:
VX-880 (Vertex Pharmaceuticals) is the most clinically advanced program, with Phase 1/2 data showing insulin independence in multiple patients. The program uses immunosuppression and is progressing toward later-stage trials. Vertex has filed for regulatory discussions with the FDA regarding the path to approval (ClinicalTrials.gov, NCT04786262).
VX-264 (Vertex Pharmaceuticals) is in Phase 1/2 trials using encapsulated stem cell-derived islets without immunosuppression. Results have been more modest, and the program is evaluating next-generation device designs.
CTX211 (CRISPR Therapeutics) is in preclinical and early clinical development, using CRISPR-edited iPSC-derived beta cells with the hypoimmunogenic engineering strategy. This program represents the gene-editing-first approach and is being closely watched as a potential immunosuppression-free solution.
Sernova Cell Pouch is in clinical trials evaluating the pre-vascularized pouch approach with cadaveric islets, with plans to incorporate stem cell-derived cells in future iterations.
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to VX-880, which provides enhanced interactions with the agency and the potential for accelerated approval pathways.
Challenges Remaining
Despite the remarkable progress, significant challenges remain before gene-edited beta cell therapy becomes a widely available cure for T1D.
Immune Evasion Durability
The gene-editing strategy for immune evasion is elegant in theory, but its long-term durability in humans is unproven. Will the engineered immune-evasion mechanisms hold up over years and decades? Could the immune system find alternative pathways to attack the transplanted cells? Could the edited cells themselves evolve or lose their protective modifications over time? These questions can only be answered with extended clinical follow-up.
Safety of Hypoimmunogenic Cells
Cells that are invisible to the immune system raise a theoretical safety concern: if one of the transplanted cells undergoes malignant transformation, the immune system would be unable to detect and eliminate it. This is why several groups are incorporating inducible "safety switches" -- genetic kill switches that can be activated with an external drug to destroy the transplanted cells if needed. The design and reliability of these safety mechanisms are critical to regulatory approval.
Glucose Responsiveness at Scale
Manufacturing billions of stem cell-derived beta cells that are uniformly mature and glucose-responsive is a substantial bioengineering challenge. Differentiation protocols have improved dramatically, but the resulting cell populations are not 100 percent pure. Immature or off-target cells in the product could reduce efficacy or pose safety risks. Quality control at manufacturing scale -- ensuring that every batch meets stringent specifications for identity, purity, potency, and sterility -- is an ongoing area of development.
Vascularization and Engraftment
Whether delivered by portal vein infusion, subcutaneous implantation, or encapsulation device, transplanted beta cells must receive adequate blood supply to survive and function. The omentum, kidney capsule, subcutaneous space, and hepatic portal system have all been evaluated as implantation sites, each with trade-offs in accessibility, vascularization, and retrievability.
"The site of implantation is not a trivial detail," noted Dr. Alice Tomei, associate professor of biomedical engineering at the University of Miami. "Where you put the cells determines whether they live or die, how quickly they respond to glucose, and whether you can retrieve them if something goes wrong" (Diabetes Research Institute, University of Miami).
Manufacturing Cost and Scalability
Even if the science works perfectly, the cost of manufacturing personalized or semi-personalized cell therapies remains high. iPSC-derived, CRISPR-edited beta cell products will need to be manufactured at a scale and cost that makes them accessible to the 8.7 million people living with T1D worldwide -- including in low- and middle-income countries where the disease burden is growing fastest. The universal donor approach helps by allowing a single manufacturing run to serve many patients, but the per-dose cost of a multi-gene-edited, stem cell-derived cell therapy product will still be substantial.
Expert Perspectives on the Path Forward
The convergence of stem cell biology and gene editing has generated cautious optimism among researchers and clinicians.
Dr. James Shapiro, the architect of the Edmonton Protocol and a professor at the University of Alberta, has been characteristically measured: "What Vertex has shown with VX-880 is that the cells work. That is not a small thing -- it is a scientific and clinical milestone. But the path from 'the cells work with immunosuppression' to 'the cells work without immunosuppression, in a device or with gene editing, at scale, at reasonable cost' is still long. We should be hopeful and honest at the same time" (University of Alberta, Department of Surgery).
Dr. Felicia Pagliuca, co-founder of Semma Therapeutics (acquired by Vertex) and one of the developers of the SC-beta cell differentiation protocol, has emphasized the importance of the manufacturing challenge: "People focus on the immunology, which is obviously critical. But the manufacturing piece is equally important. You need to produce billions of high-quality cells, consistently, affordably, and at a scale that serves a global patient population. That requires industrial bioprocess engineering at a level that the field is still developing" (Cell, 2014).
What a Cure Would Mean
It is worth pausing to consider what a functional cure for Type 1 diabetes would mean in human terms.
A child diagnosed with T1D at age eight currently faces an estimated 19,000 insulin injections, 50,000 finger pricks, and thousands of hours managing blood glucose levels over the course of their lifetime. They face a life expectancy reduction of approximately eight to 13 years compared to their non-diabetic peers, driven primarily by cardiovascular and renal complications (Livingstone et al., JAMA, 2015). They face social stigma, psychological burden, employment discrimination, insurance battles, and the relentless cognitive load of a disease that never takes a day off.
A single infusion or implantation of gene-edited beta cells that restores glucose-responsive insulin production -- without immunosuppression, without devices, without daily management -- would transform this trajectory entirely. It would be, for millions of people, a liberation.
The economic implications are also staggering. The lifetime cost of managing T1D in the United States is estimated at $800,000 to $1.2 million per patient, including insulin, devices, supplies, medical visits, and complications management (American Diabetes Association, Diabetes Care, 2023). Even an expensive one-time cell therapy could be cost-effective relative to decades of chronic disease management.
Timeline and Realistic Expectations
Where does this leave patients who are waiting for a cure? The honest answer is that functional cures for T1D are closer than they have ever been, but they are not imminent for the general patient population.
VX-880, the most advanced program, could potentially receive regulatory approval within the next two to four years for a narrowly defined patient population -- likely patients with severe hypoglycemia unawareness who are at high risk of life-threatening episodes. This first-generation product will require immunosuppression.
Gene-edited, immunosuppression-free products like CTX211 are likely several years behind, given the additional complexity of validating the immune-evasion strategy in humans. Regulatory agencies will require robust long-term safety data before approving a hypoimmunogenic cell product for a chronic (but non-fatal in the short term) condition.
Broad availability -- where any person with T1D can receive a curative cell therapy as a standard of care -- is likely a decade or more away, contingent on manufacturing scale-up, cost reduction, regulatory approval across multiple jurisdictions, and the resolution of remaining scientific questions about durability and safety.
But the trajectory is clear. The science works. The cells can be made. The immune barriers can be engineered around. What remains is execution -- and that is a fundamentally different kind of problem than the unsolved scientific questions that characterized this field a decade ago.
Conclusion: From Management to Medicine
For a century, insulin has kept people with Type 1 diabetes alive. It is one of the great achievements of modern medicine. But insulin is a treatment, not a cure. It replaces a missing hormone without replacing the cells that should produce it. It manages a chronic condition without resolving the underlying disease.
Gene editing, combined with stem cell biology, offers something categorically different: the prospect of replacing the destroyed beta cells with new ones that the immune system cannot attack. CRISPR Therapeutics' CTX211, Vertex's VX-880, and the broader ecosystem of academic and industry programs are converging on a common vision -- a single procedure that restores the body's ability to regulate its own blood sugar, eliminating the need for exogenous insulin, devices, and daily management.
The challenges are real. The timeline is uncertain. The cost will be high, at least initially. But for 8.7 million people living with a disease that demands constant vigilance and offers no respite, the trajectory of this research represents something that has been absent for a very long time: genuine, scientifically grounded hope for a cure.
Sources
-
Gregory, G.A., et al. "Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040." The Lancet Diabetes & Endocrinology, 2022. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00218-2/fulltext
-
Shapiro, A.M.J., et al. "Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen." New England Journal of Medicine, 2000. https://www.nejm.org/doi/full/10.1056/NEJM200007273430401
-
Pagliuca, F.W., et al. "Generation of Functional Human Pancreatic Beta Cells In Vitro." Cell, 2014. https://doi.org/10.1016/j.cell.2014.09.040
-
CRISPR Therapeutics Regenerative Medicine Pipeline. https://www.crisprtx.com/programs/regenerative-medicine
-
Vertex Pharmaceuticals VX-880 Clinical Program. https://news.vrtx.com/
-
ClinicalTrials.gov. VX-880 Phase 1/2 Trial (NCT04786262). https://clinicaltrials.gov/ct2/show/NCT04786262
-
Sernova Corp Cell Pouch System. https://www.sernova.com/
-
Livingstone, S.J., et al. "Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes." JAMA, 2015. https://jamanetwork.com/journals/jama/fullarticle/2089370
-
American Diabetes Association. "Economic Costs of Diabetes in the U.S." Diabetes Care, 2023. https://diabetesjournals.org/care
-
Harvard Stem Cell Institute, Douglas Melton Laboratory. https://hsci.harvard.edu/
-
Diabetes Research Institute, University of Miami. https://www.diabetesresearch.org/
-
University of Alberta, Department of Surgery -- James Shapiro Research Group. https://www.ualberta.ca/surgery/
